[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Yamaguchi J, Akashi-Tanaka S, Fukutomi T, Kinosita T, Iwamoto E, Takasugi M: A case of mucinous carcinoma of the breast that demonstrated a good pathological response to neoadjuvant chemotherapy despite a poor clinical response. Breast Cancer; 2006;13(1):100-3
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of mucinous carcinoma of the breast that demonstrated a good pathological response to neoadjuvant chemotherapy despite a poor clinical response.
  • A 30-year-old woman presented with a right breast tumor.
  • Mucinous carcinoma was diagnosed by core needle biopsy (T2: 5 cm N1 M0).
  • Based on the patient's strong preference, we performed breast-conserving surgery.
  • On histological examination, we observed widespread mucus and a few viable malignant cells, a Grade 2 therapeutic response.
  • Neither optimal management procedures nor guidelines for chemotherapy for primary mucinous carcinoma of the breast have been established.
  • It is a reasonable assumption, however, that discordance between the clinical response and therapeutic response to neoadjuvant chemotherapy may occur in cases of mucinous carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Paclitaxel / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518069.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Shimazu K, Tamaki Y, Taguchi T, Akazawa K, Inoue T, Noguchi S: Sentinel lymph node biopsy using periareolar injection of radiocolloid for patients with neoadjuvant chemotherapy-treated breast carcinoma. Cancer; 2004 Jun 15;100(12):2555-61
Hazardous Substances Data Bank. Isosulfan blue .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy using periareolar injection of radiocolloid for patients with neoadjuvant chemotherapy-treated breast carcinoma.
  • BACKGROUND: The feasibility and accuracy of sentinel lymph node (SLN) biopsy after neoadjuvant chemotherapy (NAC) for patients with breast carcinoma have been investigated primarily for the situation in which the radiocolloid imaging agent is injected peritumorally.
  • No such study has involved periareolar injection of radiocolloid, although the usefulness of this injection technique has been demonstrated in patients with early-stage breast carcinoma who have not been treated with NAC.
  • The objective of the current study was to determine the feasibility and accuracy of SLN biopsy using periareolar injection of radiocolloid for patients with breast carcinoma who were treated with NAC.
  • METHODS: Forty-seven patients with AJCC Stage II or III breast carcinoma who were treated with NAC were enrolled in the study.
  • All patients underwent SLN biopsy, which involved a combination of periareolar injection of radiocolloid (technetium 99m tin colloid) and peritumoral injection of isosulfan blue dye, followed by backup axillary lymph node dissection.
  • In patients with clinically negative axillary lymph nodes both before and after NAC, SLN biopsy was capable of predicting axillary lymph node status with an accuracy comparable to the accuracy associated with SLN biopsy for patients with early-stage carcinoma who have not been treated with NAC.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / diagnosis. Lymphatic Metastasis / diagnosis. Sentinel Lymph Node Biopsy / methods. Technetium Compounds. Tin Compounds
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Feasibility Studies. Female. Humans. Injections. Lymph Node Excision. Neoadjuvant Therapy. Rosaniline Dyes

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TIN COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15197796.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Rosaniline Dyes; 0 / Technetium Compounds; 0 / Tin Compounds; 0 / technetium Tc 99m tin colloid; 39N9K8S2A4 / iso-sulfan blue
  •  go-up   go-down


3. Miller AR, Thomason VE, Yeh IT, Alrahwan A, Sharkey FE, Stauffer J, Otto PM, McKay C, Kahlenberg MS, Phillips WT, Cruz AB Jr: Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol; 2002 Apr;9(3):243-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma.
  • BACKGROUND: Sentinel lymph node mapping (SLNM) and neoadjuvant chemotherapy are becoming established components of therapy for selected patients with breast carcinoma.
  • However, neoadjuvant therapy has been considered a relative contraindication to SLNM.
  • In an effort to learn whether patients who have received preoperative chemotherapy can undergo accurate SLNM, we evaluated our experience with this technique.
  • METHODS: From January 1997 to June 2000, SLNM and axillary lymph node dissection were concurrently performed in 35 patients who received preoperative chemotherapy.
  • Mapping was performed with (99m)Tc sulfur colloid only in one patient and Lymphazurin dye only in 15 patients, and the two methods were combined in the remainder.
  • The intraoperative pathologic diagnosis proved to be correct in 19 (79%) of 24 patients.
  • The final pathologic diagnosis of the sentinel lymph node reflected the status of the axillary contents in all patients in whom it was identified.
  • CONCLUSIONS: These results demonstrate that SLNM can be consistently performed in patients receiving preoperative chemotherapy for breast cancer, suggesting the utility of this technique in this patient population.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Case-Control Studies. Female. Humans. Mastectomy, Segmental. Neoadjuvant Therapy. Patient Selection. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2002 Apr;9(3):217-9 [11923125.001]
  • (PMID = 11923130.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Nason KS, Anderson BO, Byrd DR, Dunnwald LK, Eary JF, Mankoff DA, Livingston R, Schmidt RA, Jewell KD, Yeung RS, Moe RE: Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer; 2000 Dec 1;89(11):2187-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma.
  • BACKGROUND: Sentinel lymph node dissection (SLND) has been a promising new technique in breast carcinoma staging, but could be unreliable in certain patient subsets.
  • The current study assessed whether age, preoperative chemotherapy, tumor size, and/or previous excisional biopsy influenced the identification of sentinel nodes (SLNs) or the reliability of a node-negative SLND in predicting a node negative axilla.
  • SLNDs were performed using both technetium-99m (Tc-99m) labeled colloid and isosulfan blue dye.
  • Mapping success was decreased among postmenopausal women but was not influenced by preoperative chemotherapy, large tumor size, or previous excisional biopsy.
  • Of the 9 successfully mapped patients who had received preoperative chemotherapy and had positive axillary nodes, 3 had FN SLND (FN rate = 33%).
  • The presence of clinically positive lymph nodes before chemotherapy did not predict which patients would have a subsequent FN SLND.
  • No FN SLND occurred with T1/T2 tumors that were not excised previously and had not received preoperative chemotherapy.
  • CONCLUSIONS: Preoperative chemotherapy was associated with an unacceptably high FN rate for SLND.
  • While larger tumor size also was associated with FN SLND, this effect might have been due to preoperative chemotherapy use in these patients.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. False Negative Reactions. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Postmenopause. Predictive Value of Tests. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11147588.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA72064
  • [Publication-type] Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


5. Olszewski W: Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema. Angiology; 2000 Jan;51(1):25-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Micronized purified flavonoid fraction (MPFF) is a phlebotropic drug commonly used to treat the signs and symptoms associated with chronic venous insufficiency (CVI).
  • It has confirmed its clinical efficacy in different groups of patients suffering from edema: idiopathic cyclic edema, CVI-associated edema, postmastectomy lymphedema and might be beneficial in some of drug-induced edema.
  • In this study, a significant decrease in circumference of the most affected leg was observed after 2 months of treatment (p<0.001), whatever the schedule of administration of MPFF (1000 mg once daily or bid).
  • The mean volume of the more affected lower leg decreased significantly after a 6-week period of treatment, correlating to a significant improvement in clinical symptoms.
  • MPFF has been also tested on another type of edema, upper limb lymphedema secondary to mastectomy, during a double-blind, placebo-controlled, randomized study in 104 patients.
  • MPFF 1000 mg/day improved all lymphoscintigraphic parameters such as half-life and clearance of the labelled colloid.
  • Based on its action on capillary hyperpermeability, MPFF has been used with attractive results when combined with classic treatment for a pilot study carried out in patients with advanced breast cancer (n=21) or ovarian carcinoma (n=3), treated with docetaxel, which causes severe edema as a side effect, even when associated with corticoids.
  • These results in different types of edema confirm that, by acting on all parameters involved in edema, veins, lymphatics, and microcirculation, MPFF represents a drug of choice for treating CVI-associated edema.
  • [MeSH-major] Edema / drug therapy. Flavonoids / therapeutic use. Leg. Taxoids. Venous Insufficiency / complications
  • [MeSH-minor] Anthropometry. Antineoplastic Agents, Phytogenic / adverse effects. Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Capillary Permeability / drug effects. Carcinoma / drug therapy. Double-Blind Method. Electronics, Medical. Female. Humans. Lymphedema / drug therapy. Mastectomy / adverse effects. Optics and Photonics. Ovarian Neoplasms / drug therapy. Paclitaxel / adverse effects. Paclitaxel / analogs & derivatives. Placebos. Randomized Controlled Trials as Topic. Weight Loss

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10667640.001).
  • [ISSN] 0003-3197
  • [Journal-full-title] Angiology
  • [ISO-abbreviation] Angiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Placebos; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Shibaki T, Morimoto N: [A case of postoperative liver metastasis of mucinous carcinoma of the breast with complete response to sequential administration of FEC75, tamoxifen citrate, and letrozole]. Gan To Kagaku Ryoho; 2010 Mar;37(3):499-501
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of postoperative liver metastasis of mucinous carcinoma of the breast with complete response to sequential administration of FEC75, tamoxifen citrate, and letrozole].
  • A 51-year-old woman, who had undergone mastectomy due to a mucinous carcinoma of her left breast, was diagnosed with solitary liver metastasis 7 months after operation.
  • Systemic chemotherapy consisting of 5 courses of FEC75 (cyclophosphamide 500 mg/m2, epirubicin 75 mg/m2, and 5-FU 500 mg/m2 on 1st day, with 1 course for 21 days) was followed by sequential hormonal therapy with tamoxifen citrate and letrozole.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Nitriles / therapeutic use. Tamoxifen / therapeutic use. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. LETROZOLE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332691.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Triazoles; 094ZI81Y45 / Tamoxifen; 3Z8479ZZ5X / Epirubicin; 7LKK855W8I / letrozole; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Owens CL, Basaria S, Nicol TL: Metastatic breast carcinoma involving the thyroid gland diagnosed by fine-needle aspiration: a case report. Diagn Cytopathol; 2005 Aug;33(2):110-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast carcinoma involving the thyroid gland diagnosed by fine-needle aspiration: a case report.
  • The distinction of metastatic carcinoma (MC) or sarcoma from a primary thyroid malignancy is important because the treatment is different.
  • We discuss a case of a 64-yr-old female with a history of breast carcinoma, who presented with pain and swelling in her neck 5 yrs after being diagnosed with breast cancer.
  • She had undergone mastectomy with subsequent chemotherapy and radiation for infiltrating mammary carcinoma.
  • A fine-needle aspiration (FNA) of the larger thyroid nodule showed malignant epithelial cells with features consistent with breast carcinoma in a background of benign thyroid epithelial cells and colloid.
  • The case was signed out as metastatic breast carcinoma.
  • Subsequent FNA and biopsy of her right shoulder lesion also revealed metastatic breast carcinoma with similar morphology to the material in the thyroid FNA.
  • [MeSH-major] Carcinoma, Ductal, Breast. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Breast Neoplasms / complications. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Female. Humans. Middle Aged. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16007653.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Gimbergues P, Abrial C, Durando X, Le Bouedec G, Cachin F, Penault-Llorca F, Mouret-Reynier MA, Kwiatkowski F, Maublant J, Tchirkov A, Dauplat J: Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol; 2008 May;15(5):1316-21
Hazardous Substances Data Bank. TIN COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.
  • BACKGROUND: In breast cancer, neoadjuvant chemotherapy (NAC) is widely used in order to enable a conservative surgery.
  • METHODS: Between March 2001 and December 2006, 129 patients with infiltrating breast carcinoma were studied prospectively.
  • CONCLUSION: Our results show that clinical nodal status is the main clinicopathological factor influencing the false-negative rate of SLN biopsy after NAC for breast cancer.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Neoadjuvant Therapy. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Axilla. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / secondary. False Negative Reactions. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Prognosis. Prospective Studies. Radiopharmaceuticals. Technetium Compounds. Tin Compounds

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18311507.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0 / Technetium Compounds; 0 / Tin Compounds; 0 / technetium Tc 99m tin colloid
  •  go-up   go-down


9. Benedetto N, Perrini P, Scollato A, Buccoliero AM, Di Lorenzo N: Intracranial meningioma containing metastatic colon carcinoma. Acta Neurochir (Wien); 2007 Aug;149(8):799-803; discussion 803
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningioma containing metastatic colon carcinoma.
  • Meningioma is the most common intracranial tumour to host metastases, the majority of which arise from breast and lung cancers.
  • Her medical history included resection of an adenocarcinoma of the descending colon followed by adjuvant chemotherapy 1 year before our evaluation.
  • The pathological examination demonstrated a mixture of fibrous meningioma and colloid adenocarcinoma.
  • [MeSH-minor] Aged. Colectomy. Craniotomy. Female. Humans. Magnetic Resonance Imaging. Postoperative Complications / diagnosis. Postoperative Complications / pathology. Postoperative Complications / surgery. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660939.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


10. Pendas S, Dauway E, Giuliano R, Ku N, Cox CE, Reintgen DS: Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol; 2000 Jan-Feb;7(1):15-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy in ductal carcinoma in situ patients.
  • BACKGROUND: Sentinel lymph node (SLN) mapping is an effective and accurate method of evaluating the regional lymph nodes in breast cancer patients.
  • METHODS: At Moffitt Cancer Center, 87 patients with newly diagnosed pure ductal carcinoma in situ (DCIS) lesions were evaluated by using CK IHC staining of the SLN.
  • Patients with any focus of microinvasive disease, detected on diagnostic breast biopsy by routine H&E, were excluded from this study.
  • DCIS patients, with biopsy-proven in situ tumor by routine H&E stains, underwent intraoperative lymphatic mapping, using a combination of vital blue dye and technetium-labeled sulfur colloid.
  • All SLNs that had only CK-positive cells were subsequently confirmed malignant by a more detailed histological examination of the nodes.
  • RESULTS: CK IHC staining was performed on 177 SLNs in 87 DCIS breast cancer patients.
  • Of interest, four of the five node-positive patients had comedo carcinoma associated with the DCIS lesion, and one patient had a large 9.5-cm low grade cribriform and micropapillary type of DCIS.
  • CONCLUSIONS: This study confirms that lymphatic mapping in breast cancer patients with DCIS lesions is a technically feasible and a highly accurate method of staging patients with undetected micrometastatic disease to the regional lymphatic basin.
  • This procedure can be performed with minimal morbidity, because only one or two SLNs, which are at highest risk for containing metastatic disease, are removed.
  • Because most patients with DCIS lesions detected by routine H&E stains do not have regional lymph node metastases, these patients can safely avoid the complications associated with a complete axillary lymph node dissection and systemic chemotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Axilla. Biopsy. Female. Humans. Intraoperative Period. Lymphatic Metastasis. Neoplasm Staging. Prospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2001 Sep;8(8):617-9 [11569773.001]
  • (PMID = 10674443.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


11. Liang H, Ye F, Lembersky BC, Bhargava R: Correlation of WT1 expression with tumor characteristics and clinical outcomes in mucinous breast carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e22075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of WT1 expression with tumor characteristics and clinical outcomes in mucinous breast carcinoma.
  • : e22075 Background: Wilms' tumor 1(WT1) protein expression has been evaluated by immunohistochemistry (IHC) in various histologies of series of invasive breast carcinomas.
  • It is overexpressed predominantly in the mucinous subtype, in both pure and mixed mucinous carcinoma.
  • The objective of this study was to correlate WT1 expression with the clinical and biological features of mucinous breast carcinoma as well as with the clinical outcomes and management.
  • METHODS: A total of 83 cases of pure and mixed mucinous breast carcinoma diagnosed between January 1999 and May 2006 were selected from the Magee-Womens Hospital, University of Pittsburgh Medical Center pathology registry.
  • WT1 expression was examined by IHC using tissue microarrays (TMA).
  • Sixty four cases had sufficient tissue on TMA for WT1 expression.
  • Among them, WT1 expression was identified in 21/33 (64%) of pure mucinous carcinomas and 9/31 (29%) of mixed type tumors.
  • Patients in both WT1-positive and WT1-negative groups had similar rates of breast conserving surgery, adjuvant radiotherapy and endocrine therapies.
  • More patients with WT1-negative tumors received adjuvant chemotherapy (40.6% vs 13.8%, p=0.02).
  • CONCLUSIONS: Overall, both pure and mixed mucinous breast carcinomas have excellent prognosis.
  • This retrospective study demonstrated that WT1 expression may be associated with favorable outcome/pathologic features for patients with mucinous breast carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963217.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Schwartz GF: Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: current update. Breast J; 2004 Mar-Apr;10(2):85-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: current update.
  • Axillary sentinel lymph node biopsy (SLNB) has been adopted as a suitable alternative to traditional level I and II axillary dissection in the management of clinically node-negative (N0) breast cancers.
  • There are two current techniques used to identify the sentinel node(s): radiopharmaceutical, technetium sulfur colloid, and isosulfan blue dye (used in the United States) and technetium-labeled albumin and patent blue dye (used in Europe). (The labeled albumin is not U.S.
  • Food and Drug Administration [FDA] approved in the United States.
  • Immunochemical staining with cytokeratin or other techniques to identify "submicroscopic" metastasis is often used, but the results should not be used to influence clinical decisions with respect to adjuvant therapy.
  • Although SLNB was initiated to accompany breast-conserving treatment, it is equally useful in patients undergoing mastectomy.
  • When using blue dye only, SLNB may require a separate incision because of time constraints between injection and identification of the blue-stained nodes; radiocolloid usually does not.
  • SLNB is a useful procedure that may save 70% of women with clinically negative (N0) axillae and all of those with pathologically negative axillae from the morbidity of complete axillary dissection.
  • [MeSH-major] Breast Neoplasms / pathology. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15009032.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 8
  •  go-up   go-down


13. Amersi F, Hansen NM: The benefits and limitations of sentinel lymph node biopsy. Curr Treat Options Oncol; 2006 Mar;7(2):141-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The status of the axilla is the single most important prognostic indicator of overall survival in patients with breast cancer.
  • The number of lymph nodes, although prognostic, no longer impacts treatment options.
  • Sentinel lymph node (SLN) mapping and dissection is a more sensitive and accurate technique for nodal evaluation and has been applied to staging of axillary lymph nodes in patients with breast cancer, providing prognostic information, with less surgical morbidity than with axillary lymph node dissection (ALND).
  • When analyzed by an experienced pathologist with serial sectioning and immunohistochemical evaluation, SLN is the most accurate detection tool used in staging of breast cancer.
  • In addition, this technique may also be therapeutic because in most patients, the SLN is the only positive axillary node.
  • SLN biopsy is justified in women with ductal carcinoma in situ who have a high risk of invasive carcinoma, such as those with large tumors, a mass, or high-grade lesions.
  • SLN biopsy is performed in the setting of neoadjuvant chemotherapy and demonstrates accurate evaluation of the axilla in 90% of the cases.
  • Women with locally advanced breast cancer may derive great benefit from a minimally invasive approach to the axilla because the extent of nodal involvement is unlikely to change further treatment.
  • For clinically palpable nodes, ALND should be performed for therapeutic and local control.
  • Vital blue dye is contraindicated in pregnant patients, although some have used radioactive colloid alone to map this subgroup of patients.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / secondary. Lymph Nodes / pathology. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Axilla. Female. Humans. Lymphatic Metastasis. Mastectomy. Neoadjuvant Therapy. Pregnancy. Pregnancy Complications, Neoplastic / therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucl Med Commun. 2001 Apr;22(4):361-6 [11338045.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2187-94 [11147588.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):272-7 [11923134.001]
  • [Cites] Surgery. 2000 Jul;128(1):6-12 [10876178.001]
  • [Cites] Cancer Treat Rev. 2005 Jun;31(4):283-302 [15916855.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):354-8 [15725804.001]
  • [Cites] CA Cancer J Clin. 2000 Sep-Oct;50(5):279-91 [11075238.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2345-50 [9196149.001]
  • [Cites] Eur J Surg Oncol. 2003 Mar;29(2):118-20 [12633552.001]
  • [Cites] Ann Surg Oncol. 2005 Nov;12 (11):895-9 [16195833.001]
  • [Cites] Ann Surg Oncol. 2001 Oct;8(9):688-92 [11597008.001]
  • [Cites] J Surg Res. 1999 Jun 15;84(2):138-42 [10357910.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):101-9 [10458223.001]
  • [Cites] Ann Surg. 2003 May;237(5):732-8; discussion 738-9 [12724640.001]
  • [Cites] Oncologist. 2005 Apr;10(4):242-9 [15821244.001]
  • [Cites] Br J Surg. 1986 Jul;73(7):580-4 [3730795.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):243-7 [11923130.001]
  • [Cites] Cancer J Sci Am. 1997 Nov-Dec;3(6):336-40 [9403045.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1137-46 [15674853.001]
  • [Cites] Lancet. 1997 Jun 28;349(9069):1864-7 [9217757.001]
  • [Cites] Ann Oncol. 1999 Jan;10(1):47-52 [10076721.001]
  • [Cites] J Natl Cancer Inst Monogr. 1997;(22):151-6 [9709292.001]
  • [Cites] Am J Surg. 2000 Oct;180(4):274-7 [11113434.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2540-5 [10861431.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):81-9 [10862199.001]
  • [Cites] J Surg Oncol. 2003 Oct;84(2):63-7 [14502778.001]
  • [Cites] J Am Coll Surg. 1998 Apr;186(4):423-7 [9544956.001]
  • [Cites] Arch Surg. 1992 Apr;127(4):392-9 [1558490.001]
  • [Cites] N Engl J Med. 2002 Oct 17;347(16):1233-41 [12393820.001]
  • [Cites] Pathol Oncol Res. 1998;4(4):301-3 [9887361.001]
  • [Cites] Eur J Cancer. 1994;30A(5):645-52 [8080680.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3C):2167-71 [9703779.001]
  • [Cites] Am J Surg. 2001 Oct;182(4):407-10 [11720681.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):235-42 [11923129.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):931-42 [12875603.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2483-93 [9215816.001]
  • [Cites] N Engl J Med. 2002 Oct 17;347(16):1227-32 [12393819.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jan;89(2):159-63 [15692758.001]
  • [Cites] Ann Surg. 1995 Sep;222(3):394-9; discussion 399-401 [7677468.001]
  • [Cites] Breast J. 2004 Nov-Dec;10 (6):492-5 [15569204.001]
  • [Cites] Am J Surg. 2001 Oct;182(4):312-5 [11720661.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):1-7 [10862188.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54 [12381707.001]
  • [Cites] Am J Surg. 2005 Feb;189(2):229-35 [15720997.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):77-84 [9887158.001]
  • [Cites] Ann Surg. 2000 May;231(5):724-31 [10767794.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):181-7 [2910416.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1368-77 [11745212.001]
  • [Cites] Oncology. 1993 Nov-Dec;50(6):445-9 [8233285.001]
  • [Cites] CA Cancer J Clin. 2002 Sep-Oct;52(5):277-300 [12363326.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1080-4 [11571718.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2560-6 [10893287.001]
  • [Cites] BMJ. 2005 Oct 8;331(7520):789-90 [16210257.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):261-9 [3276824.001]
  • [Cites] Am J Surg. 2002 Jan;183(1):23-7 [11869698.001]
  • [Cites] J Am Coll Surg. 2005 Jan;200(1):10-4 [15631914.001]
  • [Cites] Surg Oncol. 1993 Dec;2(6):335-9; discussion 340 [8130940.001]
  • [Cites] N Engl J Med. 2003 Aug 7;349(6):546-53 [12904519.001]
  • [Cites] N Engl J Med. 1998 Oct 1 ;339(14 ):941-6 [9753708.001]
  • [Cites] Eur J Surg Oncol. 2003 May;29(4):341-50 [12711287.001]
  • [Cites] Ann Surg Oncol. 1999 Jul-Aug;6(5):450-4 [10458682.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17 ):1297-306 [11535704.001]
  • [Cites] Clin Breast Cancer. 2004 Aug;5(3):235-8 [15335458.001]
  • [Cites] Ann Surg Oncol. 2002 Oct;9(8):745-53 [12374657.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3480-6 [11032588.001]
  • [Cites] Am J Surg. 2005 Oct;190(4):563-6 [16164920.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):391-8; discussion 398-401 [8092905.001]
  • [Cites] Cancer Clin Trials. 1981 Fall;4(3):229-36 [7026073.001]
  • [Cites] Ann Surg Oncol. 2000 Jan-Feb;7(1):21-7 [10674444.001]
  • [Cites] Eur J Surg Oncol. 2005 Apr;31(3):232-6 [15780556.001]
  • (PMID = 16455025.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


14. Ishikawa T, Hamaguchi Y, Ichikawa Y, Shimura M, Kawano N, Nakatani Y, Ohnishi H, Maegawa J, Ogino I, Shimada H: Locally advanced mucinous carcinoma of the breast with sudden growth acceleration: a case report. Jpn J Clin Oncol; 2002 Feb;32(2):64-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced mucinous carcinoma of the breast with sudden growth acceleration: a case report.
  • We report a 35-year-old woman with locally advanced mucinous carcinoma of the breast with sudden growth acceleration.
  • A pea-sized mass developed into an ulcerated large tumor within 1 month.
  • After the combination of chemotherapy, radiation and hyperthermia, a radical mastectomy was performed, followed by repair of the skin defect by latissimus dorsi and rectus abdominis musculocutaneous flaps.
  • Histological examination revealed a pure mucinous carcinoma with axillary lymph node involvement.
  • Twenty-five months after treatment, there is no sign of recurrent disease.
  • Pure mucinous carcinoma generally has a less aggressive growth pattern as defined by tumor size, adherence to the overlying skin/bottom fasciae, estrogen and progesterone receptor positive and primary lymph axillary lymph node metastases.
  • This case showed completely opposite features to all of these typical biological features of pure mucinous carcinomas.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Breast Neoplasms / therapy. Mastectomy, Radical
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease Progression. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Female. Humans. Paclitaxel / administration & dosage. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11948231.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. Chok KS, Suen DT, Lim FM, Li GK, Kwong A: Factors affecting false-negative breast sentinel node biopsy in Chinese patients. ANZ J Surg; 2007 Oct;77(10):866-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting false-negative breast sentinel node biopsy in Chinese patients.
  • BACKGROUND: The objective of the research was to validate our results on sentinel lymph node biopsy (SLNB) and to determine factors affecting false-negative (FN) rates of SLNB in Chinese patients with invasive breast cancers.
  • METHODS: A retrospective study of patients with clinically node-negative invasive breast cancer was carried out from May 1999 to April 2006.
  • A combination of radioisotope (99m)technetium(Tc)-albumin sulfur colloid and Patent Blue V dye was used to identify the sentinel lymph node.
  • Seventy-eight patients with neoadjuvant chemotherapy and 56 patients with in situ carcinoma were excluded.
  • [MeSH-major] Breast Neoplasms / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. China. False Negative Reactions. Female. Humans. Lymph Node Excision. Mastectomy. Middle Aged. Reoperation / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17803550.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement